Alembic Pharmaceuticals Limited (NSE:APLLTD)

Alembic Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	1,430	834.8	1,202	754.8	610.9	980.6
Trading Asset Securities	-	-	-	-	-	1,870
Cash & Short-Term Investments	1,430	834.8	1,202	754.8	610.9	2,850
Cash Growth	10.92%	-30.55%	59.26%	23.55%	-78.57%	296.76%
Accounts Receivable	13,139	13,998	10,248	10,464	8,071	3,486
Other Receivables	94.5	110.1	477.5	827.1	250.8	166
Receivables	13,234	14,108	10,726	11,291	8,322	3,652
Inventory	25,407	22,881	16,435	14,753	16,097	14,862
Prepaid Expenses	-	691.8	500.5	553.2	370.7	357.3
Other Current Assets	3,426	2,362	1,922	1,748	3,207	4,799
Total Current Assets	43,497	40,878	30,786	29,100	28,608	26,520
Property, Plant & Equipment	35,147	33,608	30,711	29,997	39,473	36,472
Long-Term Investments	1,292	1,272	930.2	963.3	1,184	493.1
Other Intangible Assets	2,220	-	-	-	1,548	3,238
Long-Term Deferred Tax Assets	1,652	1,660	1,696	1,230	58.8	-
Other Long-Term Assets	161.7	311.5	332.9	537.4	348.8	367.2
Total Assets	83,969	77,729	64,456	61,828	71,220	67,090
Accounts Payable	8,874	8,799	7,356	6,798	7,064	6,688
Accrued Expenses	-	1,828	1,582	1,418	1,850	1,832
Short-Term Debt	-	11,956	4,305	6,359	4,300	0.2
Current Portion of Long-Term Debt	13,740	-	-	-	2,000	2,999
Current Portion of Leases	309.3	151.6	198.3	169.2	149.8	122.8
Current Income Taxes Payable	567.9	189.1	-	-	-	21.5
Current Unearned Revenue	-	115.6	114.5	112.7	123.6	118.6
Other Current Liabilities	3,811	1,085	994.2	1,512	1,678	1,027
Total Current Liabilities	27,302	24,123	14,550	16,369	17,165	12,808
Long-Term Debt	399.5	-	-	-	-	1,999
Long-Term Leases	438.2	467.7	628.8	692.3	721.4	715.4
Pension & Post-Retirement Benefits	-	270.9	90.2	57.2	-	-
Long-Term Deferred Tax Liabilities	-	-	-	-	-	42.1
Other Long-Term Liabilities	2,669	972.2	1,005	1,005	958.1	855.3
Total Liabilities	30,809	25,834	16,274	18,124	18,845	16,420
Common Stock	393.1	393.1	393.1	393.1	393.1	393.1
Additional Paid-In Capital	-	7,484	7,484	7,484	7,484	7,484
Retained Earnings	-	43,945	40,273	35,687	43,991	41,550
Comprehensive Income & Other	52,800	87.8	32.4	140.8	507.2	1,243
Total Common Equity	53,193	51,909	48,182	43,705	52,376	50,670
Minority Interest	-32.8	-14.2	-	-	-	-
Shareholders' Equity	53,160	51,895	48,182	43,705	52,376	50,670
Total Liabilities & Equity	83,969	77,729	64,456	61,828	71,220	67,090
Total Debt	14,887	12,575	5,132	7,220	7,171	5,836
Net Cash (Debt)	-13,457	-11,740	-3,930	-6,465	-6,560	-2,986
Net Cash Per Share	-68.50	-59.73	-19.99	-32.89	-33.37	-15.41
Filing Date Shares Outstanding	196.5	196.56	196.56	196.56	196.56	196.56
Total Common Shares Outstanding	196.5	196.56	196.56	196.56	196.56	196.56
Working Capital	16,195	16,755	16,236	12,731	11,443	13,712
Book Value Per Share	270.70	264.09	245.12	222.34	266.46	257.78
Tangible Book Value	50,973	51,909	48,182	43,705	50,827	47,432
Tangible Book Value Per Share	259.41	264.09	245.12	222.34	258.58	241.31
Land	-	1,070	1,013	1,017	931.4	1,138
Buildings	-	7,810	7,465	7,068	5,277	5,084
Machinery	-	30,646	28,487	24,961	18,291	16,399
Construction In Progress	-	8,372	5,244	6,013	22,058	19,443
Leasehold Improvements	-	36	18.3	7.9	7.3	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.